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Pyrrolnitrin is the active ingredient of drugs for the treatment of superﬁcial
fungal infections and was used as a lead structure for the development of
ﬂudioxonil. It is an effective agent for plant diseases caused by the fungal
pathogen Rhizoctonia solani. Pyrrolnitrin is made in four steps, the second of
which, catalyzed by PrnB, is a novel chemical rearrangement of 7-chloro-
tryptophan. PrnB was overproduced in Pseudomonas ﬂuorescens (BL915) and
well diffracting crystals were obtained of a triple cysteine-to-serine mutant by
sitting-drop vapour diffusion. Crystals grown in the presence of l-7-chloro-
tryptophan, d-tryptophan and l-tryptophan are reported. Data sets for each are
reported with high-resolution limits of 2.0, 1.75 and 1.75 A ˚ , respectively. Two
crystals (PrnB in the presence of d-tryptophan and l-7-chlorotryptophan)
belong to space group C2 with similar unit-cell parameters (a = 68.6, b = 79.5,
c =9 2 . 7 A ˚ ,  =  = 90.0,  = 103.8 ). Crystals grown in the presence of
l-tryptophanbelongtospacegroupC2221andhaveunit-cellparametersa=67.7,
b = 80.1, c = 129.5 A ˚ . All crystals contain a monomer in the asymmetric unit.
1. Introduction
Pyrrolnitrin [3-chloro-4-(20-nitro-30-chlorophenyl)pyrrole; Fig. 1] is a
tryptophan-derived secondary metabolite with broad-spectrum anti-
fungal activity which was ﬁrst isolated in 1964 from Pseudomonas
pyrrocinia (Arima et al., 1964). Subsequently, pyrrolnitrin has been
identiﬁed in several isolates of Pseudomonas and Burkholderia
(previously named Pseudomonas). It has been implicated as an
important mechanism of biological control of soil-borne fungal plant
pathogens by these strains (Homma et al., 1989; Howell & Stipanovic,
1979; Janisiewicz & Roitman, 1987). Pyrrolnitrin production has also
been documented for strains of Enterobacter agglomerans (Chernin et
al., 1996), Myxococcus fulvus (Gerth et al., 1982), Corallococcus
exiguous (Gerth et al., 1982), Cystobacter ferrugineus (Gerth et al.,
1982) and Serratia spp. (Kalbe et al., 1996). Tryptophan was identiﬁed
as a pyrrolnitrin precursor by feeding cultures with isotopically
labelled compounds. Both d- and l-tryptophan isomers were efﬁ-
ciently incorporated into pyrrolnitrin. The pyrrolnitrin biosynthetic
gene cluster from P. ﬂuorescens (BL915) was ﬁnally identiﬁed in 1997
(van Pee & Ligon, 2000; Hammer et al., 1997; Kirner et al., 1998). This
led to a proposal of the pathway for pyrrolnitrin biosynthesis (Fig. 1).
The ﬁrst and third steps are catalyzed by two related enzymes, PrnA
and PrnC. Both PrnA and PrnC belong to the ﬂavin-dependent
halogenase superfamily. The structure and mechanism of PrnA have
been elucidated (Dong et al., 2005; Yeh et al., 2006).
The transformation catalyzed by PrnB has no obvious chemical
precedent. Although tryptophan-degrading enzymes such as indol-
amine dioxygenase and tryptophan dioxygenase are well known
(Brady, 1975), both result in oxygen-containing compounds. This is
not the case for PrnB; there is no additional oxygen in the product
and PrnB decarboxylates its substrate. Sequence-comparison
methods do not identify any protein with convincing homology to
PrnB, further complicating any attempt to rationalize the chemical
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2. Purification and site-directed mutagenesis
Genomic DNA was extracted from P. ﬂuorescens (BL915) using the
Qiagen Blood and Cell Culture DNA Kit. An overnight culture
(10 ml) of P. ﬂuorescens (BL915) was processed on a genomic DNA-
puriﬁcation column. Genomic DNA quality was assessed by running
DNA gels. The DNA for PrnB was cloned using gene-speciﬁc primers
and the clones were checked by sequencing. The veriﬁed PrnB cDNA
was ligated into a variety of Escherichia coli expression vectors, but
none gave soluble protein. The failure to express soluble PrnB in
E. coli led us to investigate its expression in P. ﬂuorescens (BL915).
We employed the same P. ﬂuorescens (BL915) ORF1-4 expression
strain that had successfully been employed in the study of PrnA
(Dong et al., 2004, 2005; Keller et al., 2000). In this strain, all four
enzymes in the pyrrolnitrin pathway have been deleted from the
chromosome. The prnB ORF was cloned into the pCIB-HIS vector,
which was used for PrnA overexpression in P. ﬂuorescens (BL915)
ORF1-4 (Dong et al., 2004, 2005; Keller et al., 2000). This vector
contains an N-terminal His tag. E. coli TOP10 cells were transformed
with pCIB-HIS containing the PrnB insert and grown to produce a
stock of high-quality plasmid DNA. Some plasmid was transformed
into E. coli S17.1 strain. The E. coli strain was mixed with P. ﬂuor-
escens (BL915) ORF1-4 and the plasmid was transferred between
the bacteria by conjugation. Plasmid DNA was extracted from
tetracycline-resistant clones of P. ﬂuorescens (BL915) ORF1-4.
Clones carrying the correct plasmids were chosen for protein
expression. P. ﬂuorescens (BL915) ORF1-4 cells were grown as
described previously (Dong et al., 2004).
pCIB-HIS-prnB gave overexpression of soluble His-PrnB, which
was conﬁrmed by mass spectrometry. For analysis of in vitro activity,
one part cells was resuspended in two parts 50 mM potassium
phosphate buffer pH 7.2 and lysed by sonication. The addition of
100 mM d/l-7-chlorotrytophan to the cell lysate containing His-PrnB
led to the production of monodechloroaminopyrrolnitrin. The
presence of this product was conﬁrmed by HPLC analysis according
to a previously published method (van Pee et al., 1980; Hohaus et al.,
1997). Control samples (heat-treated or no His-PrnB) gave no such
product. For puriﬁcation of PrnB, cells were harvested by centrifu-
gation and lysed by sonication on ice into 20 mM Tris–HCl pH 7.5,
100 mM NaCl. The soluble fraction was applied onto a 5 ml Ni
2+ Hi-
Trap column and eluted with an increasing gradient of imidazole (0–
400 mM). Fractions containing His-PrnB were pooled before running
on a Superdex S200 gel-ﬁltration column. The protein ran incon-
sistently between batches, but always showed at least two peaks
corresponding to a monomer and a dimer. The presence of 5 mM
dithiothreitol (DTT) resulted in predominantly the monomeric
species. This protein was concentrated to 16 mg ml
 1, but failed to
give useful crystals using Nextal Classics, JSGS+ (Qiagen) and
Hampton PEG/Ion crystallization kits.
The sensitivity of the gel-ﬁltration proﬁle to DTT suggested that
PrnB was aggregating owing to disulﬁde-bond formation. As a result,
we decided to mutate all three Cys residues to Ser (C21S, C60S and
C175S). The P. ﬂuorescens (BL915) PrnB triple mutant (tmPrnB) was
created using the QuickChange Multi Site-Directed Mutagenesis Kit.
Only one round of mutagenesis was required and the following
primers were used (the mutation is marked in bold and the changed
triplet is underlined): 50-C21S, ACGCTGCCGTGGCGGCCTCC-
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Figure 1
The biosynthetic pathway of pyrrolnitrin. The reaction catalyzed by PrnB is highlighted.CGATCCGCTGCAGGC; 50-C60S, GCGCGGCCTGCCCTCCG-
GCTGGGGTTTCGTCGAAGC; 50-C175S. CGAGTTCGCGCAA-
AGGTCCGACGAGCTGGAAGCC; 30-C21S, CGCGCCTGCAG-
CGGATCGGAGGCCGCCACGGCAGC; 30-C60S, GACGAAAC-
CCCAGCCGGAGGGCAGGCCGCGCACCGG; 30-C175S, CTT-
CCAGCTCGTCGGACCTTTGCGCGAACTCGG. tmPrnB was
puriﬁed in the same way as native protein. It showed the same activity
in feeding experiments. Crucially, gel ﬁltration showed a single
species consistent with a monomer independent of the addition of
DTT.
3. Crystallization and X-ray data collection
For crystallization experiments, tmPrnB was concentrated to
16 mg ml
 1 (measured by the Bradford assay) in 20 mM Tris–HCl pH
7.2. Saturated solutions of each enantiomer of tryptophan were used;
saturated solutions were made by agitating excess solid material with
the protein solution. The precise concentration of the tryptophan is
therefore unknown. Crystallization trials were set up at the Scottish
Structural Proteomic Facility with a nanodrop crystallization robot
(Cartesian HoneyBee) on sitting-drop plates (Hampton Research
CrystalQuick 96) using Nextal Classics, JCSG+ (Qiagen) and
Hampton PEG/Ion crystallization kits. Each drop contained 200 nl
protein solution plus 200 nl precipitant in vapour equilibrium with
100 ml precipitant. We failed to obtain crystals of protein unless
tmPrnB was ﬁrst incubated with tryptophan. Crystals were obtained
from only one condition (during the four weeks of observation),
which was the same for both d- and l-tryptophan. This crystallization
condition was optimized independently for both incubations by
increasing drop size and systematically varying the pH and precipi-
tant concentration. The best results (judged by crystal appearance)
were obtained using sitting-drop plates (Hampton Research Crys-
talClear Strips 96-well plates) with 1.5 ml protein solution
(16 mg ml
 1) plus 1.5 ml precipitant [0.22 M magnesium sulfate,
16%(w/v) PEG 3350] irrespective of whether protein was incubated
with d-o rl-tryptophan. Crystals tended to grow (but not always) as
cluster of plates/rods, both habits being visible within the same well.
We have been able to grow crystals of protein incubated with
l-7-chlorotryptophan (using the same method of saturating the
solution) under the same conditions. Irrespective of the incubating
ligand, the crystals typically measure 0.2   0.2   <0.05 mm. A plate
was detached using a loop from a crystal cluster obtained from
protein pre-incubated with l-tryptophan. The plate was cryopro-
tected with 20% (R,R)-2,3-butanediol (Fig. 2). Data were collected at
100 Kon Station 9.6 at the Synchrotron Radiation Source, UK (SRS)
using an ADSC Quantum 4 CCD. A single plate-shaped crystal
grown in the presence of d-tryptophan was cryoprotected in the same
way and a data set was collected at 100 K on beamline ID29 using an
ADSC Quantum 4 CCD. A single rod-shaped crystal grown in the
presence of l-7-chlorotryptophan was cryoprotected in the same way
and a data set was collected on Station 20 at the SRS using an ADSC
Quantum 4 CCD. All three data sets were collected as a series of 0.5 
oscillations. All images were indexed in MOSFLM (Leslie, 1992) and
merged with SCALA (Evans, 1997) as implemented in the CCP4
package (Collaborative Computational Project, Number 4, 1994).
Full statistics are given in Table 1. Interestingly, the unit cells of the
l-tryptophan-incubated crystals appear to be related to the other two
(with a and b common), but the data are distinct. The lower symmetry
space group for the crystals grown in the presence of d-tryptophan
and 7-chlorotryptophan appears to be correct; we failed to index
either in higher symmetry. Matthews solvent-content calculations
suggest that all crystals contain a monomer in the asymmetric unit,
but the l-tryptophan-grown crystals contain signiﬁcantly less solvent.
4. Results and discussion
We have obtained good-quality crystals of PrnB from P. ﬂuorescens
(BL915) grown in the presence of substrate and two substrate mimics.
The lack of homology of PrnB to proteins of known structure has
ruled out molecular replacement as a possible method of structure
solution. Therefore, we will have to use experimental phasing
methods relying on the incorporation of anomalous scatters. We have
shown the P. ﬂuorescens (BL915) system can be used to incorporate
selenium in much the same way as in E. coli (Dong et al., 2004). As
the crystals give high-quality data, we expect this to be straightfor-
ward. In both crystals, we have obtained the result that there is a
monomer in the asymmetric unit. The mutation of Cys to Ser to
prevent aggregation hasbeen used in other systems (Pesce et al., 2003;
Vallone et al., 2004) and was essential here. Once again, the
P. ﬂuorescens (BL915) expression system has provided a relatively
simple method of rescuing apparently ‘insoluble’ protein from E. coli
expression systems. The yield of the pure PrnB is around 5 mg from
1 l of culture. The system therefore possibly merits wider use in the
structural biology community. We expect that a structural analysis of
crystallization communications
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Figure 2
A crystal of PrnB grown in the presence of l-tryptophan and mounted for data
collection.
Table 1
X-ray data collection on PrnB.
Values in parentheses are for the outer shell.
d-Trp l-Trp l-7-Cl-Trp
Resolution limits (A ˚ ) 51–1.75 (1.84–1.75) 38–1.75 (1.84–1.75) 51.0–1.90 (2.00–1.90)
Wavelength 0.9762 1.4880 1.2830
Unit-cell parameters
(A ˚ ,  )
a = 68.2, b = 79.5,
c = 92.3,
 =  = 90,
 = 103.4
a = 67.7, b = 80.1,
c = 129.5,
 =  =  =9 0
a = 68.5, b = 79.5,
c = 93.1,
 =  = 90,
 = 103.7
Space group C2 C2221 C2
Unique reﬂections 47277 (6791) 35216 (4879) 36544 (4608)
Multiplicity (%) 3.7 (3.8) 4.4 (4.0) 2.6 (1.8)
Completeness (%) 97.5 (96.3) 98.1 (94.3) 95.8 (83.0)
Rmerge 0.073 (0.666) 0.082 (0.193) 0.065 (0.437)
I/(I) 12.7 (2.0) 16.0 (4.2) 13.0 (2.0)
Solvent content (%)
With one monomer 55 39 55
With two monomers 12 <0 12PrnB will shed light on the chemical mechanism of this fascinating
enzyme.
JHN is a BBSRC Career Development Fellow. The project was
funded by a BBSRC grant on pyrrolnitrin biosynthesis to JHN.
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